155 related articles for article (PubMed ID: 33214672)
1. Effect of digestion on stability of palivizumab IgG1 in the infant gastrointestinal tract.
Lueangsakulthai J; Kim BJ; Demers-Mathieu V; Sah BNP; Woo Y; Olyaei A; Aloia M; O'Connor A; Scottoline BP; Dallas DC
Pediatr Res; 2021 Aug; 90(2):335-340. PubMed ID: 33214672
[TBL] [Abstract][Full Text] [Related]
2. Binding and Neutralizing Capacity of Respiratory Syncytial Virus (RSV)-Specific Recombinant IgG Against RSV in Human Milk, Gastric and Intestinal Fluids from Infants.
Demers-Mathieu V; Lueangsakulthai J; Qu Y; Scottoline BP; Dallas DC
Nutrients; 2020 Jun; 12(7):. PubMed ID: 32605037
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
[TBL] [Abstract][Full Text] [Related]
4. Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model.
Lueangsakulthai J; Sah BNP; Scottoline BP; Dallas DC
Nutrients; 2020 Feb; 12(3):. PubMed ID: 32120792
[TBL] [Abstract][Full Text] [Related]
5. Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation.
Sah BNP; Lueangsakulthai J; Kim BJ; Hauser BR; Woo Y; Olyaei A; Aloia M; O'Connor A; Scottoline B; Pastey MK; Dallas DC
Front Nutr; 2020; 7():130. PubMed ID: 32923453
[TBL] [Abstract][Full Text] [Related]
6. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
Detalle L; Stohr T; Palomo C; Piedra PA; Gilbert BE; Mas V; Millar A; Power UF; Stortelers C; Allosery K; Melero JA; Depla E
Antimicrob Agents Chemother; 2016 Jan; 60(1):6-13. PubMed ID: 26438495
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
[TBL] [Abstract][Full Text] [Related]
8. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
Claydon J; Sur A; Callejas A; Ladd M; Kwan E; Taylor R; Turvey SE; Solimano A; Lavoie PM; Marr N
PLoS One; 2017; 12(4):e0176152. PubMed ID: 28437470
[TBL] [Abstract][Full Text] [Related]
11. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
[TBL] [Abstract][Full Text] [Related]
12. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
13. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
Groothuis JR; Nishida H
Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
[TBL] [Abstract][Full Text] [Related]
14. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection.
Tiwari PM; Vanover D; Lindsay KE; Bawage SS; Kirschman JL; Bhosle S; Lifland AW; Zurla C; Santangelo PJ
Nat Commun; 2018 Oct; 9(1):3999. PubMed ID: 30275522
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.
Chen Z; Zhang L; Tang A; Callahan C; Pristatsky P; Swoyer R; Cejas P; Nahas D; Galli J; Cosmi S; DiStefano D; Hoang VM; Bett A; Casimiro D; Vora KA
PLoS One; 2016; 11(6):e0156798. PubMed ID: 27258388
[TBL] [Abstract][Full Text] [Related]
17. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
Zhu Q; McAuliffe JM; Patel NK; Palmer-Hill FJ; Yang CF; Liang B; Su L; Zhu W; Wachter L; Wilson S; MacGill RS; Krishnan S; McCarthy MP; Losonsky GA; Suzich JA
J Infect Dis; 2011 Mar; 203(5):674-82. PubMed ID: 21208913
[TBL] [Abstract][Full Text] [Related]
18. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.
Hiatt A; Bohorova N; Bohorov O; Goodman C; Kim D; Pauly MH; Velasco J; Whaley KJ; Piedra PA; Gilbert BE; Zeitlin L
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):5992-7. PubMed ID: 24711420
[TBL] [Abstract][Full Text] [Related]
19. Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.
Jounai N; Yoshioka M; Tozuka M; Inoue K; Oka T; Miyaji K; Ishida K; Kawai N; Ikematsu H; Kawakami C; Shimizu H; Mori M; Ishii KJ; Takeshita F
EBioMedicine; 2017 Feb; 16():124-135. PubMed ID: 28111238
[TBL] [Abstract][Full Text] [Related]
20.
van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
